Terms: = Liver cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
15 results:
1. Development of braf V600E Mutation in NRAS Q61L Mutated Rectal cancer.
Cao MN; Chen KT; Li QF; Wang L; Jin GW; Na RT; Ma J; Liu YT; Gao JL
Ann Clin Lab Sci; 2021 Mar; 51(2):262-266. PubMed ID: 33941568
[TBL] [Abstract] [Full Text] [Related]
2. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
[TBL] [Abstract] [Full Text] [Related]
3. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.
Dong F; Yang Q; Wu Z; Hu X; Shi D; Feng M; Li J; Zhu L; Jiang S; Bao Z
Biomed Pharmacother; 2019 Jun; 114():108856. PubMed ID: 30981109
[TBL] [Abstract] [Full Text] [Related]
4. A clinical trial of somatic and germline analyses for healthy longevity in a postoperative cancer patient.
Hayashi N; Kuroda Y; Saito T; Tsuruda Y; Niida A; Otsu H; Eguchi H; Masuda T; Suzuki Y; Natsugoe S; Mimori K
Surg Today; 2019 Sep; 49(9):738-747. PubMed ID: 30843125
[TBL] [Abstract] [Full Text] [Related]
5. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal cancer According to Tumor RAS and braf Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract] [Full Text] [Related]
6. New therapeutic options for advanced non-resectable malignant melanoma.
Stadler S; Weina K; Gebhardt C; Utikal J
Adv Med Sci; 2015 Mar; 60(1):83-8. PubMed ID: 25596540
[TBL] [Abstract] [Full Text] [Related]
7. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract] [Full Text] [Related]
8. braf mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.
Yaeger R; Cercek A; Chou JF; Sylvester BE; Kemeny NE; Hechtman JF; Ladanyi M; Rosen N; Weiser MR; Capanu M; Solit DB; D'Angelica MI; Vakiani E; Saltz LB
Cancer; 2014 Aug; 120(15):2316-24. PubMed ID: 24737664
[TBL] [Abstract] [Full Text] [Related]
9. [Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma].
Sevčíková K; Ušáková V; Bartošová Z; Sabol M; Ondrušová M; Ondruš D; Spánik S
Klin Onkol; 2014; 27(1):38-44. PubMed ID: 24635436
[TBL] [Abstract] [Full Text] [Related]
10. The frequency of KRAS and braf mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.
Robertson S; Hyder O; Dodson R; Nayar SK; Poling J; Beierl K; Eshleman JR; Lin MT; Pawlik TM; Anders RA
Hum Pathol; 2013 Dec; 44(12):2768-73. PubMed ID: 24139215
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
Bruera G; Cannita K; Di Giacomo D; Lamy A; Troncone G; Dal Mas A; Coletti G; Frébourg T; Sabourin JC; Tosi M; Ficorella C; Ricevuto E
BMC Med; 2012 Nov; 10():135. PubMed ID: 23136868
[TBL] [Abstract] [Full Text] [Related]
12. The rs6983267 SNP is associated with MYC transcription efficiency, which promotes progression and worsens prognosis of colorectal cancer.
Takatsuno Y; Mimori K; Yamamoto K; Sato T; Niida A; Inoue H; Imoto S; Kawano S; Yamaguchi R; Toh H; Iinuma H; Ishimaru S; Ishii H; Suzuki S; Tokudome S; Watanabe M; Tanaka J; Kudo SE; Mochizuki H; Kusunoki M; Yamada K; Shimada Y; Moriya Y; Miyano S; Sugihara K; Mori M
Ann Surg Oncol; 2013 Apr; 20(4):1395-402. PubMed ID: 22976378
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Bokemeyer C; Bondarenko I; Hartmann JT; de Braud F; Schuch G; Zubel A; Celik I; Schlichting M; Koralewski P
Ann Oncol; 2011 Jul; 22(7):1535-1546. PubMed ID: 21228335
[TBL] [Abstract] [Full Text] [Related]
14. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/braf mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract] [Full Text] [Related]